Loading clinical trials...
Loading clinical trials...
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Amgen
NCT07669168 · Health Services Accessibility, Rural Health, and more
NCT07256249 · Cardiovascular Diseases
NCT06675552 · Heart Disease, Heart Failure, and more
NCT07613294 · Atherosclerosis, Cardiovascular Diseases, and more
NCT07517263 · Cardiovascular Disease and Lipoprotein(a)
Advanced Cardiovascular LLC
Alexander City, Alabama
University of Alabama Birmingham Saint Vincents Birmingham
Birmingham, Alabama
Birmingham Clinical Research
Birmingham, Alabama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions